Xarelto(rivaroxaban)
Xarelto (rivaroxaban) is a small molecule pharmaceutical. Rivaroxaban was first approved as Xarelto on 2008-09-30. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat acute coronary syndrome, atrial fibrillation, coronary artery disease, peripheral arterial disease, and pulmonary embolism amongst others. The pharmaceutical is active against coagulation factor X.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Xarelto
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xarelto | New Drug Application | 2023-02-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary embolism | EFO_0003827 | D011655 | I26 |
| venous thrombosis | HP_0004936 | D020246 | I82.40 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
RIVAROXABAN, XARELTO, JANSSEN PHARMS | |||
| 2025-06-20 | PED | ||
| 2025-02-23 | PED | ||
| 2024-12-20 | NP | ||
| 2024-08-23 | I-867 | ||
| 2023-09-10 | PED | ||
| 2023-04-11 | PED | ||
| 2023-03-10 | M-284 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Rivaroxaban, Xarelto, Janssen Pharms | |||
| 10828310 | 2039-01-31 | U-3207, U-3208 | |
| 9539218 | 2034-02-17 | U-1953, U-1954, U-1955, U-1957, U-2143, U-2641, U-3285, U-3288, U-3289 | |
| 9415053 | 2024-11-13 | DP | U-1167, U-1200, U-1301, U-1302, U-2142, U-2435, U-2640, U-3205, U-3206, U-3284, U-3286, U-3287 |
| 7157456 | 2024-08-28 | DS, DP | U-1301, U-1302 |
HCPCS
No data
Clinical
Clinical Trials
399 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 2 | 5 | 13 | 21 | 51 | 91 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 2 | 10 | 23 | 7 | 21 | 61 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 2 | 4 | 9 | 9 | 15 | 38 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | 1 | 4 | 6 | 13 | 23 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 4 | 8 | 6 | 6 | 21 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 3 | 2 | 7 | 4 | 16 | |
| Thrombosis | D013927 | 3 | 1 | 3 | 4 | 4 | 14 | ||
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 3 | 2 | 5 | 3 | 13 |
| Neoplasms | D009369 | C80 | 1 | 1 | 7 | 1 | 3 | 12 | |
| Peripheral arterial disease | D058729 | EFO_0004265 | 2 | — | 1 | 5 | 4 | 12 |
Show 41 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | 4 | 5 | — | 3 | 9 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 2 | 1 | 1 | — | 1 | 4 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | 1 | — | 1 | 3 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 2 | 2 | — | — | 3 |
| Rheumatic heart disease | D012214 | EFO_1001161 | I09.9 | — | — | 3 | — | — | 3 |
| Intracranial thrombosis | D020767 | 1 | 2 | 1 | — | — | 3 | ||
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | 1 | — | 1 | 2 |
| May-thurner syndrome | D062108 | — | — | 1 | — | 1 | 2 | ||
| Brain ischemia | D002545 | I67.82 | — | 1 | 1 | — | 1 | 2 | |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | 1 | — | — | 2 |
Show 27 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 13 | 2 | — | — | 1 | 16 | ||
| Bariatric surgery | D050110 | 1 | 1 | — | — | — | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
| Esophageal neoplasms | D004938 | C15 | — | 1 | — | — | — | 1 | |
| Duodenal neoplasms | D004379 | — | 1 | — | — | — | 1 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | C24.9 | — | 1 | — | — | — | 1 | |
| Ampulla of vater cancer | — | — | 1 | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Replacement arthroplasty knee | D019645 | — | — | — | — | 2 | 2 | ||
| Replacement arthroplasty hip | D019644 | — | — | — | — | 2 | 2 | ||
| Thrombophilia | D019851 | D68.59 | — | — | — | — | 1 | 1 | |
| Oral surgery | D013515 | — | — | — | — | 1 | 1 | ||
| Postoperative complications | D011183 | — | — | — | — | 1 | 1 | ||
| Oral surgical procedures | D019647 | — | — | — | — | 1 | 1 | ||
| Menorrhagia | D008595 | N92.0 | — | — | — | — | 1 | 1 | |
| Periodontal diseases | D010510 | K05.6 | — | — | — | — | 1 | 1 | |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | — | — | 1 | 1 |
| Frailty | D000073496 | R53.1 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RIVAROXABAN |
| INN | rivaroxaban |
| Description | Rivaroxaban is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. It is an anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery. It has a role as an anticoagulant and an EC 3.4.21.6 (coagulation factor Xa) inhibitor. It is a member of thiophenes, an organochlorine compound, an oxazolidinone, a member of morpholines, a lactam, an aromatic amide and a monocarboxylic acid amide. Rivaroxaban is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels. |
| Classification | Small molecule |
| Drug class | antithrombotics, blood coagulation factor XA inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1 |
Identifiers
| PDB | 2W26 |
| CAS-ID | 366789-02-8 |
| RxCUI | 1114195 |
| ChEMBL ID | CHEMBL198362 |
| ChEBI ID | 68579 |
| PubChem CID | 9875401 |
| DrugBank | DB06228 |
| UNII ID | 9NDF7JZ4M3 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Xarelto - Johnson & Johnson
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,190 documents
View more details
Safety
Black-box Warning
Black-box warning for: Xarelto
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
138,519 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more